Risks and Benefits of Scrotal Drainage in Penile Prosthesis Implant
Study Details
Study Description
Brief Summary
The goal of this prospective randomized study is to demonstrate if the use of an external scrotal drainage in penile prosthetic surgery can reduce the risk of post-operative complications without increase the risk of infections.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
After being informed about the study, all patients give writted informed consent. After that they will be randomized in two groups (A with drainage, B without drainage) using a random sequence generator. Then the patient will undergo the implantation of a three-component penile prosthesis following peri antibiotic prophylaxis with cephalosporins and aminoglycosides, the antibiotic prophylaxis will be continued on the first post-operative day surgery with a cephalosporin. In the group A it will be positioned at the scrotal level (using surgical access or using a second incision) an external drainage (10 Ch in aspiration) for 24 hours. The drainage will be removed on the first post-operative day. The degree of the hematoma will be determined using a 5-point Likert scales already approved in previous cases. Subsequently patients will carry out periodic check-ups at 7, 15 and 30 days after the operation to evaluate the appearance of hematomas and surgical site infection. After that, they will carry out check-ups every month for the first 3 months, then every 3 months for the first year and finally annually up to the fifth year after the intervention. During the clinical check-ups, it will also be defined the time of use of the penile prosthesis.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Group with drainage
|
Device: External scrotal drainage
Application of external scrotal drainage during three-component penile prosthesis placement
|
| No Intervention: Group without drainage
|
Outcome Measures
Primary Outcome Measures
- Post-operative infectious episodes [One month]
Define the number of post-operative infectious episodes in the two study arms.
Secondary Outcome Measures
- Post-surgical hematoma [One month]
Define the risk of post-surgical hematoma formation in the two study arms.
- Volume of drained material [24 hour]
Evaluate the volume of drained material in the group with external drainage.
- Manipulation of the activation pump [Up to 12 weeks]
Define the time elapsed between surgery and subsequent manipulation of the activation pump in the two study arms, usually 2 weeks.
- Activation of the device [Up to 12 weeks]
Define the time elapsed between the surgical intervention and the subsequent activation of the device in the two study arms, usually 3 weeks.
- Use of the penile prosthesis [Up to 12 weeks]
Define the time elapsed between surgery and the use of the penile prosthesis for sexual activity in the two study arms, usually 4 weeks after surgery.
- Effectiveness of external drainage in subgroups [Up to 12 months]
Compare, through a sub-analysis, the effectiveness of external drainage in different patient populations: heart patients, diabetics, duration of surgery. We will test the effectiveness of external drainage in these soubgroups using the IIEF questionnaires.
- Effectiveness of external drainage in subgroups [Up to 12 months]
Compare, through a sub-analysis, the effectiveness of external drainage in different patient populations: heart patients, diabetics, duration of surgery. We will test the effectiveness of external drainage in these soubgroups using the SSIPI questionnaires.
- Effectiveness of external drainage in subgroups [Up to 12 months]
Compare, through a sub-analysis, the effectiveness of external drainage in different patient populations: heart patients, diabetics, duration of surgery. We will test the effectiveness of external drainage in these soubgroups using the QoLPSS questionnaires.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Written informed consent signed voluntarily according to the rules of good clinical practice (Declaration of Helsinki) and national regulations (Appendix B).
-
Genetically male patient.
-
Age ≥ 18 years.
-
Patient suffering from ED of variable and/or multifactorial etiology.
-
Patient suffering from ED not responsive to iPDE-5.
-
Patient suffering from unresponsive or non-tolerant ED
Exclusion Criteria:
-
Absence of signed written informed consent (Appendix B).
-
Age <18 years.
-
Genetically female patients.
-
Patient with active peno-scrotal infection.
-
Patient with active systemic infection.
-
Immunosuppressed patient.
-
Patient with haematological pathologies that may cause an increased risk of bleeding.
-
Patients suffering from Peyronie's Disease who must undergo simultaneous plaque surgery.
-
Any condition or situation that, in the opinion of the investigator, places the patient at significant risk, may confound the results of the study, or significantly interfere with the patient's participation in the study.
-
The patient declares that it will be impossible for him to participate in follow-up consultations.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | SCDU Urologia | Torino | Italy | 10126 | |
| 2 | A.O.U. Città della Salute e della Scienza di Torino | Turin | Italy | 10126 |
Sponsors and Collaborators
- Azienda Ospedaliera Città della Salute e della Scienza di Torino
Investigators
- Principal Investigator: Falcone Mr Marco, Physician, Urology
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 833.300